Source: Fox News
Summary
A new report suggests that speeding up FDA reviews could unlock trillions of dollars in economic value and get lifesaving treatments to patients faster. Economist Tomas Philipson argues that most delays in the drug approval process stem from determining effectiveness rather than safety. The report estimates that cutting FDA effectiveness-review timelines by one year could generate over $10 trillion in economic value. Philipson also argues that faster approvals could help lower prescription drug costs by increasing competition among manufacturers.
Our Reading
As expected, the discussion returns to a familiar question.
Economist Tomas Philipson presents a report on the economic benefits of speeding up FDA reviews.
The report estimates trillions of dollars in potential economic value.
Philipson points to China’s faster, lower-cost clinical trial system as a competitive challenge.
The authors propose reforms, including greater use of artificial intelligence in drug reviews.
The debate about FDA reform enters another stage, with familiar arguments and proposed solutions.
Author: Evan Null
